Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Phase 3 data from the ACHIEVE-3 trial reveals that the investigational compound orforglipron outperformed oral semaglutide in both glycaemic control and weight reduction
doi: 10.1097/MPH.0b013e31815815ae Summary Keywords MNTI, clinicopathological features, BRAF , mutation, recurrence Citation Xia R-H, Zhang C-Y, Wang L-Z, Hu Y-H, Sun J-J, Tian Z and Li J (2021) Melanotic Neuroectodermal Tumor of Infancy: A Clinicopathological and BRAF V600E Mutation Study of 11 Cases
Cahill, K
Glycated hemoglobin A1c, lung function, and hospitalizations among adults with asthma
US$ 24.70
US$ 20.22
US$ 20.67
US$ 27.90
US$ 24.65
US$ 21.16
US$ 29.51
US$ 29.31
US$ 22.16
